Abstract
Research in the field of polymers and polymeric materials has garnered immense attention in the past few decades due to the versatile functional and structural capabilities of polymers which often can be manipulated for applications in the field of therapy and diagnosis for a host of diseases and disorders. Polymer therapeutics comprises polymer-drug and polymer-protein conjugates as well as supramolecular systems used as drug delivery systems. Although the pharmacological industry invests immensely in the design and discovery of novel drug molecules, small molecular drugs are often inefficient in targeting many diseases like deep seated low vasculature tumours, metastasized cancers and various autoimmune diseases. Coupled with a rapid clearance rate, low solubility, drug resistance and high off target toxicity these small molecular drugs often present modest benefits for a host of common diseases. In order to improve the therapeutic index of pre-existing drugs and shortening the translation from preclinical validation to clinical approval, a vast area of drug delivery research focuses on the improvement of drug carriers by various alterations. The major challenges currently faced by drug delivery systems include a low payload, transition through the desmoplastic barrier for solid tumours and high hepatic and renal clearance. In order to address these issues numerous polymer–protein and polymer-drug conjugates have been engineered and have reported to enhance the stability and pharmacokinetic properties of the active drugs. Highly toxic anticancer drugs like doxorubicin, cis-platin and gemcitabine have successfully been coupled with high molecular weight polymers to formulate targeted drug delivery agents, some of which have undergone successful clinical trials. Apart from PEGylated polymers, dendritic polymers and polyplexes with DNA or RNA moieties have also been considered as candidates for improving the therapeutic index of various drugs. Ongoing efforts in the development of polymer-based therapeutics are promising and open new horizons for personalized medicine for effective cure of various life-threatening diseases.
Highlights
Research in the field of polymers and polymeric materials has garnered immense attention in the past few decades due to the versatile functional and structural capabilities of polymers which often can be manipulated for applications in the field of therapy and diagnosis for a host of diseases and disorders
Polymer therapeutics comprises a vast field of materials including polymer-drug, polymer-protein conjugates as well as supramolecular assemblies
While small molecular drugs have demonstrated promising results throughout history, these agents are usually associated with limitations to combat several complex diseases including but not limited to cancer, various autoimmune and rheumatic diseases and diabetes
Summary
Research in the field of polymers and polymeric materials has garnered immense attention in the past few decades due to the versatile functional and structural capabilities of polymers which often can be manipulated for applications in the field of therapy and diagnosis for a host of diseases and disorders. Nanomaterials derived from such polymers which can be micelles, polymersomes or vesicles offer attractive chemical and physiologically modifiable features harnessed for drug delivery applications. While small molecular drugs have demonstrated promising results throughout history, these agents are usually associated with limitations to combat several complex diseases including but not limited to cancer, various autoimmune and rheumatic diseases and diabetes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.